S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NYSE:AORT

Artivion (AORT) Stock Price, News & Analysis

$20.27
+0.56 (+2.84%)
(As of 02/23/2024 ET)
Today's Range
$19.57
$20.28
50-Day Range
$16.71
$20.27
52-Week Range
$11.44
$20.28
Volume
259,100 shs
Average Volume
247,009 shs
Market Capitalization
$831.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50

Artivion MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
15.9% Upside
$23.50 Price Target
Short Interest
Bearish
7.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of Artivion in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$2.45 M Sold Last Quarter
Proj. Earnings Growth
123.08%
From $0.26 to $0.58 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

528th out of 939 stocks

Surgical & Medical Instruments Industry

64th out of 93 stocks


AORT stock logo

About Artivion Stock (NYSE:AORT)

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

AORT Stock Price History

AORT Stock News Headlines

Strange change at your bank
At least 41 major US banks have just made a drastic change to the way money in America works. It could have some major implications for you, your money and your retirement. But it’s crucial you understand what’s happening, before these changes get applied to your bank account.
Artivion (NYSE:AORT) PT Raised to $25.00 at Needham & Company LLC
Artivion (NYSE:AORT) PT Raised to $22.00
Artivion (NYSE:AORT) Sets New 12-Month High After Analyst Upgrade
Strange change at your bank
At least 41 major US banks have just made a drastic change to the way money in America works. It could have some major implications for you, your money and your retirement. But it’s crucial you understand what’s happening, before these changes get applied to your bank account.
AORT Apr 2024 12.500 put
Artivion's Earnings: A Preview
Artivion Inc AORT
Stifel Nicolaus Reaffirms Their Buy Rating on Artivion (AORT)
See More Headlines
Receive AORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/17/2022
Today
2/23/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Employees
1,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.50
High Stock Price Target
$25.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+15.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-30,690,000.00
Pretax Margin
-6.10%

Debt

Sales & Book Value

Annual Sales
$354 million
Cash Flow
$0.80 per share
Book Value
$6.87 per share

Miscellaneous

Free Float
38,294,000
Market Cap
$831.07 million
Optionable
Optionable
Beta
1.64
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. James Patrick Mackin (Age 57)
    Chairman, President & CEO
    Comp: $1.63M
  • Ms. Jean F. Holloway Esq. (Age 67)
    Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
    Comp: $636.72k
  • Mr. John E. Davis (Age 59)
    Senior Vice President of Global Sales & Marketing
    Comp: $609.91k
  • Dr. Marshall S. Stanton M.D. (Age 67)
    Senior VP of Clinical Research & Chief Medical Officer
    Comp: $615.55k
  • Mr. Lance E. Berry CPA (Age 52)
    Executive VP & CFO
  • Ms. Amy D. Horton CPA (Age 54)
    VP & Chief Accounting Officer
  • Mr. Matthew A. Getz (Age 54)
    VP & Chief Human Resources Officer
  • Robert C. Thomson
    VP of Research & Development














AORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Artivion stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Artivion in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AORT shares.
View AORT analyst ratings
or view top-rated stocks.

What is Artivion's stock price target for 2024?

2 Wall Street research analysts have issued 1 year price objectives for Artivion's shares. Their AORT share price targets range from $22.00 to $25.00. On average, they predict the company's stock price to reach $23.50 in the next twelve months. This suggests a possible upside of 15.9% from the stock's current price.
View analysts price targets for AORT
or view top-rated stocks among Wall Street analysts.

How have AORT shares performed in 2024?

Artivion's stock was trading at $17.88 at the start of the year. Since then, AORT shares have increased by 13.4% and is now trading at $20.27.
View the best growth stocks for 2024 here
.

Are investors shorting Artivion?

Artivion saw a decrease in short interest in January. As of January 31st, there was short interest totaling 2,750,000 shares, a decrease of 5.2% from the January 15th total of 2,900,000 shares. Based on an average daily trading volume, of 226,100 shares, the days-to-cover ratio is presently 12.2 days. Approximately 7.1% of the company's stock are sold short.
View Artivion's Short Interest
.

When is Artivion's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AORT earnings forecast
.

How were Artivion's earnings last quarter?

Artivion, Inc. (NYSE:AORT) posted its quarterly earnings data on Thursday, February, 17th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.45. The company earned $79.39 million during the quarter, compared to analyst estimates of $78 million. Artivion had a positive trailing twelve-month return on equity of 3.02% and a negative net margin of 8.67%.

What guidance has Artivion issued on next quarter's earnings?

Artivion issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $382.0 million-$396.0 million, compared to the consensus revenue estimate of $384.3 million.

Who are Artivion's major shareholders?

Artivion's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.42%), Dimensional Fund Advisors LP (4.11%), GW&K Investment Management LLC (3.01%), First Eagle Investment Management LLC (1.29%), Wasatch Advisors LP (1.27%) and Northern Trust Corp (1.05%). Insiders that own company stock include Amy Horton, Andrew M Green, David Ashley Lee, Dennis B Maier, James P Mackin, Jean F Holloway, John E Davis, Matthew A Getz and Rochelle L Maney.
View institutional ownership trends
.

How do I buy shares of Artivion?

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AORT) was last updated on 2/23/2024 by MarketBeat.com Staff